As previously reported, William Blair analyst Andy Hsieh upgraded Terns Pharmaceuticals (TERN) to Outperform from Market Perform after the company announced data from the ongoing CARDINAL trial of TERN-701 in participants with previously treated chronic myeloid leukemia. The overall major molecular response rate of 75%, with 64% achieving MMR by 24 weeks, is “impressive” and “topples investors expectations” and the competitive bar, the analyst tells investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TERN:
- Terns Pharmaceuticals upgraded to Outperform from Market Perform at William Blair
- Terns Pharmaceuticals Announces CARDINAL Trial Data Presentation
- Terns Pharmaceuticals announces data from CARDINAL trial of TERN-701
- Citizens JMP healthcare analysts hold an analyst/industry conference call
- Terns Pharmaceuticals price target lowered to $15 from $20 at Citizens JMP